Panel Discussion: Starting with the End in Mind: Strategic Access Planning at the Earliest Stages for CNS Therapeutics
Time: 8:30 am
day: Conference Day One
Details:
- CNS drugs face uniquely complex access hurdles: diagnostic ambiguity, subjective endpoints, societal stigma, infrastructure gaps, and payer scepticism toward psychiatric or neurodegenerative indications
- Market access strategy cannot wait until Phase 3 – strategy and decisions need to be made at the earliest stages of development to lock in value later
Key Questions:
- Why is it essential to begin market access planning before clinical proof of concept, particularly for CNS assets?
- How do you define and stress-test a Target Product Profile (TPP) at the pre–Phase 2 stage to align with future payer and HTA expectations?
- What is different about market access planning in CNS vs. other therapeutic areas at this stage?
